TY - JOUR
T1 - A molecular probe for detecting cholinesterase activity in MRI
AU - Sen, Sajal
AU - Dawson, Miranda
AU - Thiabaud, Gregory D.
AU - Backman, Kyle
AU - Fayer, Itay
AU - Das, Sayani
AU - Whitmire, Eliza
AU - Kung, Catherine
AU - Barandov, Ali
AU - Jasanoff, Alan
N1 - Publisher Copyright:
Copyright © 2025 the Author(s).
PY - 2025/10/14
Y1 - 2025/10/14
N2 - Cholinesterase (ChE) enzymes terminate action of the neurotransmitter acetylcholine at synapses and neuromuscular junctions throughout the body. Noninvasive strategies for monitoring these enzymes could be important for studying basic biology of cholinergic systems and disorders that affect their function. To address this goal, we developed an imaging probe that allows activity of ChE to be detected using MRI. The probe, called ChERT, undergoes enzymatic processing that reduces its solubility, promoting accumulation near sites of cholinesterase activity. Following wide-field brain delivery, ChERT produces MRI contrast changes in brain regions known to be enriched in cholinesterases; these are suppressed in the presence of a selective enzymatic inhibitor, confirming their specificity. After abdominal delivery, ChERT labels regions of the gut where ChE expression is expected. In both the brain and periphery, colocalization of ChERT with ChE could be confirmed and visualized at higher resolution by fluorescence microscopy, owing to optical properties of the probe architecture. The ChERT agent thus provides a potentially versatile basis for assessment of cholinergic phenotypes throughout the body.
AB - Cholinesterase (ChE) enzymes terminate action of the neurotransmitter acetylcholine at synapses and neuromuscular junctions throughout the body. Noninvasive strategies for monitoring these enzymes could be important for studying basic biology of cholinergic systems and disorders that affect their function. To address this goal, we developed an imaging probe that allows activity of ChE to be detected using MRI. The probe, called ChERT, undergoes enzymatic processing that reduces its solubility, promoting accumulation near sites of cholinesterase activity. Following wide-field brain delivery, ChERT produces MRI contrast changes in brain regions known to be enriched in cholinesterases; these are suppressed in the presence of a selective enzymatic inhibitor, confirming their specificity. After abdominal delivery, ChERT labels regions of the gut where ChE expression is expected. In both the brain and periphery, colocalization of ChERT with ChE could be confirmed and visualized at higher resolution by fluorescence microscopy, owing to optical properties of the probe architecture. The ChERT agent thus provides a potentially versatile basis for assessment of cholinergic phenotypes throughout the body.
KW - brain
KW - contrast agent
KW - molecular imaging
KW - neurochemistry
KW - peripheral nervous system
UR - https://www.scopus.com/pages/publications/105018248706
U2 - 10.1073/pnas.2504547122
DO - 10.1073/pnas.2504547122
M3 - Article
C2 - 41060756
AN - SCOPUS:105018248706
SN - 0027-8424
VL - 122
JO - Proceedings of the National Academy of Sciences of the United States of America
JF - Proceedings of the National Academy of Sciences of the United States of America
IS - 41
M1 - e2504547122
ER -